SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss a potential short squeeze, with some highlighting the stock's high short interest and anticipating a breakout above the $60 resistance level. The company's recent launch of a platform for menopause and perimenopause care may be acting as a catalyst, sparking bullish sentiment, while some traders are wary of familiar resistance around the $60 mark.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast is trending as the community highlights its potential for significant growth, citing its small float and EU revenue progress. Bullish investors are actively discussing the stock's undervaluation compared to competitors and anticipating a move towards higher valuations. Positive technical indicators and upcoming Q3 earnings are fueling optimism, with some eyeing a potential short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros ($OMER) is trending due to a surprise $2.1 billion deal with Novo Nordisk, sparking significant investor excitement. The community is focused on the potential for milestone payments and royalties, with many speculating about a potential short squeeze and a re-rating of the stock. Traders are closely watching resistance levels, debating whether to secure profits or hold for further gains based on the news.

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

BITF is trending as investors discuss its potential transition to AI/HPC, drawing comparisons to sector peers. Community members are closely watching key price levels and anticipating further upward movement. Bullish sentiment is fueled by the company's pivot towards AI and high-performance computing, with some speculating on potential deal announcements.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as the stock experiences volatility, with community members debating potential short squeezes and the impact of partnerships. Some traders express frustration with the stock's performance and management's communication, while others remain optimistic about its long-term potential, citing undervaluation and growth prospects. Discussions also revolve around potential acquisitions and comparisons to competitors within the insurance sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions of potential government contracts and increasing demand for antimony, particularly with China limiting exports. Community members are debating whether to hold for long-term gains or take profits after the recent surge, with some speculating about a potential short squeeze. The stock's performance is also being compared to other companies in the rare earth and critical minerals sector.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

Fueled by speculation around Trump's comments on cooking oil supply chains, Sadot Group Inc. is trending with significant after-hours volatility and high relative volume. The community is actively discussing the low float and potential for a short squeeze, with some debating its long-term value amidst the recent public offering. Others point to the company's financials and potential for a bitcoin treasury strategy as reasons for optimism.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors anticipate upcoming earnings results amid a boom in AI-related spending and strong demand for semiconductors. Community discussions revolve around potential earnings volatility and the overall strength of the AI infrastructure market, with some highlighting TSM's critical role as a chip supplier. Recent news points to increasing data center activity and partnerships within the AI sector, potentially boosting TSM's prospects.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as discussions revolve around its potential to benefit from increased U.S. focus on rare earth independence amid escalating trade tensions with China. Community members are weighing the impact of potential government investments and supply chain shifts. Bullish sentiment is tempered by concerns about overvaluation and potential pullbacks, with some traders actively trading the volatility.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to a strong earnings report and raised guidance, sparking optimism about its growth trajectory and potential profitability; the community is actively discussing the company's prospects, with some speculating about a possible buyout, fueled by increased volume and a breakout above key resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CERo Therapeutics Holdings (CERO) announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CERO">CERO stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_10_32_53_AM_png_e724743b98.webp" alt="CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="64"><figcaption>CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects a "big bounce" for the stock soon.<stembedurl>https://stocktwits.com/pharmdavid13/message/627619560</stembedurl>FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=6780690611361163">said</a>.The new designation comes weeks after the FDA granted the experimental drug an Orphan Drug designation. The FDA's Orphan Drug program is designed to advance the development of drugs that treat rare conditions affecting 200,000 or fewer US patients annually.“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable,” said CERo Therapeutics CEO Chris Ehrlich.The company is currently undertaking early-stage trials of CER-1236 in patients with acute myeloid leukemia. The study is designed to evaluate the safety and preliminary efficacy of the experimental cancer drug.Shares of the company, however, slumped 12% at the time of writing after the firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1870404/000121390025084610/ea025606902-424b3_cero.htm">said</a> on Thursday that it recently received a letter from the Nasdaq Listing Qualifications department notifying the company that it does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market.The Nasdaq staff indicated that the company’s securities would be suspended from trading on Nasdaq and delisted on Sept. 8, 2025. The company said that it subsequently requested a hearing to appeal the determination before a panel. The hearing request will stay the suspension of the trading of the company’s common stock and delisting thereof pending such hearing, it said.The company said that it intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement at the hearing. Such a plan of compliance may include an increase in stockholders’ equity through the consummation of public or private financing transactions, the company said, while adding that there can be no assurances that it will obtain a favorable decision from the hearing panel.CERO stock is down by 95% this year and by 97% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.

Equity

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.


Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML).The stock soared 189% to $19.83&nbsp;in the regular session, but fell by 15% in after-hours trading.The Phase 1/1b, open-label, multi-center clinical trial will assess the safety and initial efficacy of CER-1236 in patients with relapsed or refractory AML, remission with measurable residual disease, or newly diagnosed with TP53-mutated MDS/AML or AML.The study will include a dose escalation to determine the recommended Phase 2 dose and an expansion phase.Major objectives include the frequency of adverse events, dose-limiting toxicities, estimated overall and complete response rates, and measurable residual disease. Minor objectives include pharmacokinetics.The company said CER-1236 is designed to engineer a patient’s T cells to use phagocytic mechanisms — or target-cell “eating” — in addition to T cell destruction mechanisms.The Orphan Drug designation includes FDA assistance in clinical trial design, grants, a waiver of drug application fees, and seven years of market exclusivity upon approval.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they had accumulated shares from $8 to $15 and were still holding 4,700 shares, undecided on whether to carry the position overnight.&nbsp;<stembedurl>https://stocktwits.com/Dansaidso/message/618224240</stembedurl>Another user pointed to the stock's sharp gains, suggesting that after-hours moves were less meaningful for low-float names like Cero, which they believed could see additional upside.<stembedurl>https://stocktwits.com/SK444/message/618231176</stembedurl>Cero stock has declined 83.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

CER-1236 is designed to engineer T cells with phagocytic, or target-cell "eating," functions alongside traditional cancer-killing mechanisms. 

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7625589476402466">announced</a> an agreement with the University of California Davis to manufacture its lead compound, CER-1236, which will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia (AML).The company said that the first patient is expected to be dosed in the first half of 2025.CEO Chris Ehrlich highlighted UC Davis’ precision and compliance in manufacturing, which is critical for the successful development and execution of clinical trials.“The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward,” he said.The U.S. Food and Drug Administration (FDA) cleared the company’s application for phase 1 clinical trials of the compound in November.Earlier this month, during a scientific conference in San Diego, the company demonstrated that CER-1236 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=5472816266845157">treated</a> ovarian cancer cells without generating toxicity in animals.On Stocktwits, retail sentiment continues to trend in the ‘bullish’ territory (63/100) while message volume remains high.<figure class="image"><img style="aspect-ratio:811/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_101142_png_18b82101f9.webp" alt="CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="177"><figcaption>CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>At the end of 2024, the company faced delisting risks after its shares traded below Nasdaq’s minimum bid price requirement. Earlier this year, it announced a one-for-hundred reverse stock split of its common stock to increase its market price.In February, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7680160497345168">raised $5 million</a> through a public offering.<a href="https://stocktwits.com/symbol/CERO">Shares of CERo</a> have dropped by over 80% year-to-date and about 100% in the past 12 months. On Wednesday morning, the stock opened over 2% lower.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish

The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ('CERo') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic...

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

CERo Therapeutics Holdings Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CERO
CERo Therapeutics Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CERO News

CEROCERo Therapeutics Holdings Inc